Osteosarcoma Metastatic
8
2
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
A Look Back at How Well Interventional Treatments Work for Bronchopleural Fistulas in Patients With Lung Metastases From Osteosarcoma
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma
Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung